As scientists grapple with the implications of a CRISPR-baby world, a new analysis took an unusual approach to analyzing the risks and benefits of germline editing. For one, it was completely inside a ...

Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...

CRISPR is a technology that can be used to edit genes and, as such, will likely change the world. The essence of CRISPR is simple: it’s a way of finding a specific bit of DNA inside a cell.

Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.

CRISPR stocks are high risk but hold potential for aggressive investors. CRISPR Therapeutics and its partner Vertex Pharmaceuticals have the only approved CRISPR therapy. Several other biotech ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

CRISPR-Cas9 genome editing exploits the CRISPR ... Scientists argue that the technology involves considerable risk and uncertain benefits. Gene drive alleles bias their inheritance to spread ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...